心脏瓣膜疾病微创治疗技术---心血一线穿

2015-10-23 MedSci MedSci原创

心脏瓣膜是心脏内的一套单向阀门,一旦因为疾病发生变化,就会引起血液倒流,或是血液不能搏出,使生命失去驱动力。人类开始尝试心脏手术不过百年。直至今日,心脏瓣膜开放手术依旧是十分危险,以至于多数患者不能接受手术治疗,只能眼见生命的熄灭而无能为力。心脏瓣膜疾病微创治疗技术,通过小小的导丝,在血管内直通心脏,将心与血相连,通过微创技术将新的瓣膜植入体内,挽救燕燕欲灭生命之火。经过我国科技工作者数年攻关,已

心脏瓣膜是心脏内的一套单向阀门,一旦因为疾病发生变化,就会引起血液倒流,或是血液不能搏出,使生命失去驱动力。人类开始尝试心脏手术不过百年。直至今日,心脏瓣膜开放手术依旧是十分危险,以至于多数患者不能接受手术治疗,只能眼见生命的熄灭而无能为力。心脏瓣膜疾病微创治疗技术,通过小小的导丝,在血管内直通心脏,将心与血相连,通过微创技术将新的瓣膜植入体内,挽救燕燕欲灭生命之火。经过我国科技工作者数年攻关,已初步掌握心脏微创治疗的基本技术。今天,在中国医师协会腔内血管学分委会下,成立了国内首家心脏瓣膜疾病专家委员会,长海医院景在平教授当选主任委员,标志着我国瓣膜疾病腔内治疗走向新的篇章。

艰苦探索,厚积薄发

2002年,法国Criber教授完成世界首例主动脉瓣微创置换术,开启了心脏瓣膜疾病微创治疗时代。与此同时,我国的医生叶开始了心脏瓣膜疾病微创治疗的艰苦探索。在863计划支持下,上海长海医院心内科于2006年利用先天性心脏病封堵器的结构原理,率先提出哑铃型经导管微创主动脉瓣植入系统,开创了心脏瓣膜腔内微创治疗技术国产化研究的先河。此后,又在原有研究的基础上,设计了新型镍钛合金自膨式微创主动脉瓣移植物。2011年长海医院景在平教授团队率先开展心脏瓣膜疾微创治疗临床研究,完成国内首例经导管球扩式主动脉瓣微创置换术。目前已完成14例,成为全国完成球扩式主动脉瓣微创置换手术最多的中心。经过近10年的努力,长海医院已初步掌握心脏瓣膜微创治疗的诊疗技术与研发团队,获得国家、省市基金资助4项,获得多项专利。2014年,以景在平教授为核心,心血管内科、心脏外科、血管外科等多科室医生为骨干,成立了心脏瓣膜疾病微创诊治中心,成为国内首家以心脏瓣膜疾病为目标疾病,以微创技术为特色的跨多学科专病诊疗中心,标志着国内心脏瓣膜病腔内诊疗体系的建立与完善。

组织创新,携手并肩

心脏瓣膜疾病作为一项新生技术,由于其跨专业、跨学科,多方整合的特点,原有学术机构已不能满足其发展需要。2014年10月,中国医师协会腔内血管学分委会成立,成为国内乃至国际上首家以腔内血管学技术核心的专业学术团体。今年10月8日,其下辖心脏瓣膜疾病专家委会成立,景在平教授当选主任委员,将心脏瓣膜病纳入了我国腔内血管学发展的浪潮。与以往的学术组织不同,在专委会中,云集了来自全国近40家综合医院的专家,科室范围涵盖心血管内科、心脏外科、血管外科、超声科、介入影像科,真正实现了多中心的横向连接与多学科的纵向结合。今后的心脏瓣膜疾病微创治疗研究,不再是一家医院、一个科室的工作,而是多个学科合作的产物。集中华之才俊,筑瓣膜治疗之路;聚众家之才智,攻微创技术之坚。心脏瓣膜疾病专家委会的成立,将成为中国心脏瓣膜微创治疗研究的新起点。

浇灌爱心,刀笔一线牵

心脏瓣膜疾病微创治疗,虽然疗效确切,术后恢复迅速,但其手术费用巨大,普通患者难以承受。景在平教授有两个梦,一个是技术创新梦,一个是患者幸福梦。如何即能让大众享受先进技术带来的幸福,又不因巨大的手术费用而身背重负?自2011年起,景在平教授尝试用他自创的书画来募集爱心善款,感召全社会,共献爱心,共救老人。开启了用“技术创新梦实现患者温馨幸福梦”的新模式和新旅程。2014年感动上海十大人物评选颁奖词这样描写景在平教授, “一副军人的肩膀,挑起了人民群众的健康;一把手术刀,雕刻了无数生命的传奇。心有良知璞玉,笔下龙腾虎跃。他用宽阔的心胸,扩大了病人狭窄的心脏瓣膜,演绎了一个医者和艺者的人生传奇”。至今,景在平团队已筹措善款经500万元,爱心微创救治了十四位心脏主动脉瓣严重狭窄的濒死老人,使他们的生命和生活都得到了重生。在今年的国际腔内血管学大会中,将同时举行景在平教授书画展与心脏瓣膜专家委员会成立大会,让艺术与技术更加亲密地结合,使刀与笔更紧密地靠近,使得与会专家更加真切第感受到景在平教授的爱心,并将之播撒至五湖四海。中国的腔内心脏瓣膜微创治疗事业,将携着爱心与梦想起航。

展望未来,共同奋斗

心脏瓣膜疾病微创腔内治疗,是一项医学尖端科学,需要我国的医学工作者长期努力与奋斗。但是,在可以想见的未来,心脏瓣膜病将实现完全腔内治疗。我们有理由相信,将医生的热血与患者的信心结合,将全社会的爱心与患者的血脉相通,在主动脉瓣膜专家委员会、在景在平教授的协调领导下,必将走出一条中国特色的、世界领先的瓣膜疾病微创治疗之路,将患者的幸福梦与医者的技术梦,凝结成为瓣膜微创治疗的中国梦、世界梦。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1715917, encodeId=af961e15917ef, content=<a href='/topic/show?id=2c375156e5f' target=_blank style='color:#2F92EE;'>#心脏瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51567, encryptionId=2c375156e5f, topicName=心脏瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b6d32099965, createdName=jianjun77, createdTime=Sat Dec 26 14:46:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665774, encodeId=a6191665e7405, content=<a href='/topic/show?id=10665053ea6' target=_blank style='color:#2F92EE;'>#微创治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50537, encryptionId=10665053ea6, topicName=微创治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ad726008181, createdName=ms3046638856685384, createdTime=Sat Jul 02 15:46:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316960, encodeId=ca1e1316960ef, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sun Oct 25 00:46:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583461, encodeId=1b5a1583461b5, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Sun Oct 25 00:46:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40392, encodeId=0da340392b0, content=需要我国的医学工作者长期努力与奋斗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Fri Oct 23 12:03:00 CST 2015, time=2015-10-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1715917, encodeId=af961e15917ef, content=<a href='/topic/show?id=2c375156e5f' target=_blank style='color:#2F92EE;'>#心脏瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51567, encryptionId=2c375156e5f, topicName=心脏瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b6d32099965, createdName=jianjun77, createdTime=Sat Dec 26 14:46:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665774, encodeId=a6191665e7405, content=<a href='/topic/show?id=10665053ea6' target=_blank style='color:#2F92EE;'>#微创治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50537, encryptionId=10665053ea6, topicName=微创治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ad726008181, createdName=ms3046638856685384, createdTime=Sat Jul 02 15:46:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316960, encodeId=ca1e1316960ef, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sun Oct 25 00:46:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583461, encodeId=1b5a1583461b5, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Sun Oct 25 00:46:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40392, encodeId=0da340392b0, content=需要我国的医学工作者长期努力与奋斗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Fri Oct 23 12:03:00 CST 2015, time=2015-10-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1715917, encodeId=af961e15917ef, content=<a href='/topic/show?id=2c375156e5f' target=_blank style='color:#2F92EE;'>#心脏瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51567, encryptionId=2c375156e5f, topicName=心脏瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b6d32099965, createdName=jianjun77, createdTime=Sat Dec 26 14:46:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665774, encodeId=a6191665e7405, content=<a href='/topic/show?id=10665053ea6' target=_blank style='color:#2F92EE;'>#微创治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50537, encryptionId=10665053ea6, topicName=微创治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ad726008181, createdName=ms3046638856685384, createdTime=Sat Jul 02 15:46:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316960, encodeId=ca1e1316960ef, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sun Oct 25 00:46:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583461, encodeId=1b5a1583461b5, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Sun Oct 25 00:46:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40392, encodeId=0da340392b0, content=需要我国的医学工作者长期努力与奋斗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Fri Oct 23 12:03:00 CST 2015, time=2015-10-23, status=1, ipAttribution=)]
    2015-10-25 vera_1203
  4. [GetPortalCommentsPageByObjectIdResponse(id=1715917, encodeId=af961e15917ef, content=<a href='/topic/show?id=2c375156e5f' target=_blank style='color:#2F92EE;'>#心脏瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51567, encryptionId=2c375156e5f, topicName=心脏瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b6d32099965, createdName=jianjun77, createdTime=Sat Dec 26 14:46:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665774, encodeId=a6191665e7405, content=<a href='/topic/show?id=10665053ea6' target=_blank style='color:#2F92EE;'>#微创治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50537, encryptionId=10665053ea6, topicName=微创治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ad726008181, createdName=ms3046638856685384, createdTime=Sat Jul 02 15:46:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316960, encodeId=ca1e1316960ef, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sun Oct 25 00:46:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583461, encodeId=1b5a1583461b5, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Sun Oct 25 00:46:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40392, encodeId=0da340392b0, content=需要我国的医学工作者长期努力与奋斗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Fri Oct 23 12:03:00 CST 2015, time=2015-10-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1715917, encodeId=af961e15917ef, content=<a href='/topic/show?id=2c375156e5f' target=_blank style='color:#2F92EE;'>#心脏瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51567, encryptionId=2c375156e5f, topicName=心脏瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b6d32099965, createdName=jianjun77, createdTime=Sat Dec 26 14:46:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665774, encodeId=a6191665e7405, content=<a href='/topic/show?id=10665053ea6' target=_blank style='color:#2F92EE;'>#微创治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50537, encryptionId=10665053ea6, topicName=微创治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ad726008181, createdName=ms3046638856685384, createdTime=Sat Jul 02 15:46:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316960, encodeId=ca1e1316960ef, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sun Oct 25 00:46:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583461, encodeId=1b5a1583461b5, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Sun Oct 25 00:46:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40392, encodeId=0da340392b0, content=需要我国的医学工作者长期努力与奋斗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201205/e96b3d935daf4e258fba69d60175f0ab/b6d3ee4a3a414b8eafaf7c5e905937a2.jpg, createdBy=ad4b83208, createdName=vpssa, createdTime=Fri Oct 23 12:03:00 CST 2015, time=2015-10-23, status=1, ipAttribution=)]
    2015-10-23 vpssa

    需要我国的医学工作者长期努力与奋斗。

    0

相关资讯

经导管心脏瓣膜疾病介入治疗进展及中国发展现状

随着社会经济的发展和人口的老龄化,瓣膜性心脏病的发病率明显增加,研究表明>75岁的老年人群瓣膜性心脏病发病率高达13.3%。外科手术治疗仍是重度瓣膜病变患者的首选治疗手段,但对于高龄、合并多器官疾病 、有开胸手术史以及心功能较差的患者,Euro SCORE和(或)STS评分高,外科手术死亡率高,甚至部分患者失去了手术机会。近年来,经导管瓣膜置入/修复术逐渐